Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease

Neuroscience

Volumn 265, Issue , 2014, Pages 245-252

  Tronci, E ^a   Fidalgo, C ^a   Zianni, E ^b   Collu, M ^a   Stancampiano, R ^a   Morelli, M ^a   Gardoni, F ^b   Carta, M ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Amantadine; Dopamine; Dyskinesia; L DOPA; Memantine; NMDA receptor

Indexed keywords

AMANTADINE; BENSERAZIDE; LEVODOPA; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; OXIDOPAMINE; AMINO ACID RECEPTOR BLOCKING AGENT; ANTIPARKINSON AGENT;

ACUTE DRUG ADMINISTRATION; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CORPUS STRIATUM; DRUG ANTAGONISM; DRUG TOLERANCE; DYSKINESIA; EXPERIMENTAL MODEL; MALE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROPHYLAXIS; RAT; RECEPTOR BLOCKING; SYNAPTIC MEMBRANE; ANIMAL; CHEMICALLY INDUCED; DISEASE MODEL; DYSKINESIAS; SPRAGUE DAWLEY RAT; TOXICITY;

AMANTADINE; ANIMALS; ANTIPARKINSON AGENTS; DISEASE MODELS, ANIMAL; DYSKINESIAS; EXCITATORY AMINO ACID ANTAGONISTS; LEVODOPA; MALE; MEMANTINE; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84894665918     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2014.01.042     Document Type: Article

References (42)

1. Aarsland D., Ballard C., Walker Z., Bostrom F., Alves G., Kossakowski K., Leroi I., Pozo-Rodriguez F., Minthon L., Londos E. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2009, 8:613-618.
2. Bezard E., Tronci E., Pioli E.Y., Li Q., Porras G., Björklund A., Carta M. Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia. Mov Disord 2013, 28:1088-1096.
3. Calon F., Rajput A.H., Hornykiewicz O., Bédard P.J., Di Paolo T. Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiol Dis 2003, 14:404-416.
4. Chase T.N., Oh J.D. Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci 2000, 23(10 Suppl):S86-S91.
5. Crosby N.J., Deane K.H., Clarke C.E. Amantadine for dyskinesia in Parkinson's disease. Cochrane Database Syst Rev 2003, 2. CD003467.
6. Dekundy A., Lundblad M., Danysz W., Cenci M.A. Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav Brain Res 2007, 179:76-89.
7. Dominguez E., Chin T.Y., Chen C.P., Wu T.Y. Management of moderate to severe Alzheimer's disease: focus on memantine. Taiwan J Obstet Gynecol 2011, 50:415-423.
8. Emre M., Tsolaki M., Bonuccelli U., Destée A., Tolosa E., Kutzelnigg A., Ceballos-Baumann A., Zdravkovic S., Bladström A., Jones R., 11018 Study Investigators Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010, 9:969-977.
9. Gardoni F., Picconi B., Ghiglieri V., Polli F., Bagetta V., Bernardi G., Cattabeni F., Di Luca M., Calabresi P. A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia. J Neurosci 2006, 26:2914-2922.
10. Gardoni F., Sgobio C., Pendolino V., Calabresi P., Di Luca M., Picconi B. Targeting GluN2A-containing NMDA receptors reduces L-DOPA-induced dyskinesias. Neurobiol Aging 2012, 33:2138-2144.
11. Greulich W., Fenger E. Amantadine in Parkinson's disease: pro and contra. J Neural Transm Suppl 1995, 46:415-421.
12. Hallett P.J., Dunah A.W., Ravenscroft P., Zhou S., Bezard E., Crossman A.R., Brotchie J.M., Standaert D.G. Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Neuropharmacology 2005, 48:503-516.
13. Hanaǧasi H.A., Kaptanoglu G., Sahin H.A., Emre M. The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from L-dopa. Mov Disord 2000, 15:1016-1017.
14. Kirik D., Winkler C., Bjorklund A. Growth and functional efficacy of intrastriatal nigral transplants depend on the extent of nigrostriatal degeneration. J Neurosci 2001, 21:2889-2896.
15. Lee C.S., Cenci M.A., Schulzer M., Björklund A. Embryonic ventral mes-encephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease. Brain 2000, 123:1365-1379.
16. Leroi I., Overshott R., Byrne E.J., Daniel E., Burns A. Randomized controlled trial of memantine in dementia associated with Parkinson's disease. Mov Disord 2009, 24:1217-1221.
17. Lipton S.A. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov 2006, 5:160-170.
18. Lökk J. Memantine can relieve certain symptoms in Parkinson disease. Improvement achieved in two out of three described cases with dyskinesia and cognitive failure. Lakartidningen 2004, 101:2003-2006.
19. Luginger E., Wenning G.K., Bosch S., Poewe W. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease. Mov Disord 2000, 15:873-878.
20. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N., Cenci M.A. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci 2002, 15:120-132.
21. Lundblad M., Usiello A., Carta M., Håkansson K., Fisone G., Cenci M.A. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Exp Neurol 2005, 194:66-75.
22. Mellone M., Gardoni F. Modulation of NMDA receptor at the synapse: promising therapeutic interventions in disorders of the nervous system. Eur J Pharmacol 2013, 719:75-83.
23. Merello M., Nouzeilles M.I., Cammarota A., Leiguarda R. Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study. Clin Neuropharmacol 1999, 22:273-276.
24. Metman L.V., Del Dotto P., LePoole K., Konitsiotis S., Fang J., Chase T.N. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol 1999, 56:1383-1386.
25. Moreau C., Delval A., Tiffreau V., Defebvre L., Dujardin K., Duhamel A., Petyt G., Hossein-Foucher C., Blum D., Sablonnière B., Schraen S., Allorge D., Destée A., Bordet R., Devos D. Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study. J Neurol Neurosurg Psychiatry 2013, 84:552-555.
26. Ory-Magne F., Corvol J.C., Azulay J.P., Bonnet A.M., Brefel-Courbon C., Damier P., Dellapina E., Destée A., Durif F., Galitzky M., Lebouvier T., Meissner W., Thalamas C., Tison F., Salis A., Sommet A., Viallet F., Vidailhet M., Rascol O., On behalf of the NS-Park CIC Network Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. Neurology 2014, 82:300-307.
27. Parsons C.G., Danysz W., Quack G. Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist - a review of preclinical data. Neuropharmacology 1999, 38:735-767.
28. Parsons C.G., Gilling K. Memantine as an example of a fast, voltage-dependent, open channel N-methyl-d-aspartate receptor blocker. Methods Mol Biol 2007, 403:15-36.
29. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1998, Academic Press, San Diego.
30. Rabey J.M., Nissipeanu P., Korczyn A.D. Efficacy of memantine, an NMDA antagonist, in the treatment of Parkinson's disease. J Neural Transm Park Dis Dement Sect 1992, 4:277-282.
31. Robelet S., Melon C., Guillet B., Salin P., Kerkerian-Le Goff L. Chronic L-DOPA treatment increases extracellular glutamate levels and GLT1 expression in the basal ganglia in a rat model of Parkinson's disease. Eur J Neurosci 2004, 20:1255-1266.
32. Sanz-Clemente A., Nicoll R.A., Roche K.W. Diversity in NMDA receptor composition: many regulators, many consequences. Neuroscientist 2013, 19:62-75.
33. Sawada H., Oeda T., Kuno S., Nomoto M., Yamamoto K., Yamamoto M., Hisanaga K., Kawamura T., Amantadine Study Group Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial. PLoS ONE 2010, 5:e15298.
34. Schallert T., Tillerson J. Intervention strategies for degeneration of dopamine neurons in parkinsonism: optimising behavioral assessment of outcome. Innovative models of CNS disease; from molecule to therapy 1999, 131-151. Human Press, Clifton, NJ.
35. Schulz H., Jobert M., Coppola R., Herrmann W.M., Pantev M. The use of diurnal vigilance changes in the EEG to verify vigilance-enhancing effects of memantine in a clinical pharmacological study. Neuropsychobiology 1996, 33:32-40.
36. Shannon K.M., Goetz C.G., Carroll V.S., Tanner C.M., Klawans H.L. Amantadine and motor fluctuations in chronic Parkinson's disease. Clin Neuropharmacol 1987, 10:522-526.
37. Thomas A., Iacono D., Luciano A.L., Armellino K., Di Iorio A., Onofrj M. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry 2004, 75:141-143.
38. Tronci E., Lisci C., Stancampiano R., Fidalgo C., Collu M., Devoto P., Carta M. 5-Hydroxy-tryptophan for the treatment of l-DOPA-induced dyskinesia in the rat Parkinson's disease model. Neurobiol Dis 2013, 60:108-114.
39. Varanese S., Howard J., Di Rocco A. NMDA antagonist memantine improves levodopa-induced dyskinesias and "on-off" phenomena in Parkinson's disease. Mov Disord 2010, 25:508-510.
40. Vidal E.I., Fukushima F.B., Valle A.P., Villas Boas P.J. Unexpected improvement in levodopa-induced dyskinesia and on-off phenomena after introduction of memantine for treatment of Parkinson's disease dementia. J Am Geriatr Soc 2013, 61:170-172.
41. Witt A., Macdonald N., Kirkpatrick P. Memantine hydrochloride. Nat Rev Drug Discov 2004, 3:109-110.
42. Wolf E., Seppi K., Katzenschlager R., Hochschorner G., Ransmayr G., Schwingenschuh P., Ott E., Kloiber I., Haubenberger D., Auff E., Poewe W. Long-term antidyskinetic efficacy of amantadine in Parkinson's disease. Mov Disord 2010, 25:1357-1363.